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Al~ract----Chronic administration of a psychomotor stimulant has been shown to produce progressively 
enhanced effects, a phenomenon called "reverse tolerance" or sensitization. Sensitization which develops 
to the psychomotor stimulant effect of a drug generalizes to drugs with similar neurochemical mechanisms 
of action, a phenomenon called cross-sensitization. The present study compared the psychomotor stimulant 
effects of phencyclidine and MK-801, examined the effects of the daily injection of phencyclidine and 
MK-801 on locomotor activity and investigated whether reciprocal cross-sensitization occurred between 
phencyclidine and MK-801. Adult female Sprague-Dawley rats were used. Their locomotor activity was 
measured automatically for a 2 h period following drug injection. Phencyclidine and MK-801 both increased 
locomotor activity. Four daily injections of phencyclidine in a dose of 3.2 mg/kg i.p., or MK-801 in a dose 
of 0.32 mg/kg i.p., produced sensitization to locomotor activity. Moreover, MK-801 sensitized rats showed 
cross-sensitization to phencyclidine. However, phencyclidine sensitized rats did not show cross-sensitization 
to MK-801. This finding suggests that there are significant differences in the neurochemical mechanisms 
underlying phencyclidine-induced and MK-80 l-induced sensitization. Phencyclidine sensitization may not 
be mediated by NMDA receptors. 
Phencyclidine (PCP) is known to inhibit striatal dopa- 
mine (DA) reuptake, facilitate its release and affect its 
synthesis and metabolism in rodents (Johnson and 
Jones, 1990). In addition, PCP also has anti- 
cholinergic properties (Finnegan et al., 1976 ; Murray, 
1983), interacts with the a-receptor (Quirion et al., 
1988) and affects brain norepinephrine (NE) and sero- 
tonin (5-HT) (Johnson and Jones, 1990). Although 
PCP exerts its effects through several neurotransmitter 
systems, understanding of its mechanism of action has 
been greatly enhanced since PCP was observed to 
selectively reduce the excitatory actions of glutamate 
on spinal neurons that were mediated by N-methyl-D- 
aspartate (NMDA) receptors (Anis et al., 1983). 
The NMDA receptor mediates ion fluxes through 
a channel permeable to Na +, K +, and Ca 2+. The 
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ion flux is voltage dependent and is gated by M8 a+. 
Phencyclidine acts at a distinct site within the channel 
itself. The mechanism by which PCP inhibits NMDA- 
mediated responses is noncompetitive (Harrison and 
Simmonds, 1985; Snell and Johnson, 1986). Although 
it seems that the anticonvulsive and neuroprotective 
effects are the results of blockade of ionic conductance 
through the NMDA-operated ion channel, the neural 
bases of the psychotomimetic properties of PCP 
remain unclear. 
Receptor binding studies indicate that PCP binds 
to at least two major sites in brain tissue : a PCP site 
that is associated with NMDA receptors and a a- 
receptor site that may modulate the release of a num- 
ber of neurotransmitters (McCullough and Salamone, 
1992). The acute locomotor stimulant effects of PCP 
and SKF-10,047, a PCP as well as a ligand are similar 
with reciprocal cross-sensitization (Iwamoto, 1986; 
Greenberg and Segal, 1986). These findings suggest 
that the neural basis of the psychotomimetic effects of 
PCP may, at least in part, be the result of an inter- 
action with a-receptors. Phencyclidine also binds to a 
channel site associated with NMDA receptors, which 
may also account for its psychotomimetic effect. 
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Numerous  studies suggest that PCP and MK-801 act 
at the same channel associated with the N M D A  recep- 
tor (Anis et al., 1983 ; Fagg, 1987 ; Harrison and Sim- 
monds,  1985). MK-801, a noncompeti t ive antagonist  
at the N M D A  receptor (Wong et al., 1986) with little 
or no affinity for the o'-receptor (Wong ('t al., 1988), 
has become an impor tant  pharmacological  tool for 
studying N M D A  receptor function. To investigate 
whether antagonism of  N M D A  receptors by PCP 
accounts for its psychotomimetic  effect, comparisons 
between the locomotor  stimulant effects of  PCP and 
MK-801 may shed light on this issue. The present 
study had three objectives. The lirst was to compare 
the locomotor  stimulant effects of  PCP and MK-801 
after acute administrat ion to rats. The second was 
to determine if sensitization develops after repeated 
administrat ion of  either PCP or MK-801. Third, 
whether PCP and MK-801 show cross-sensitization. 
EXPERIMENTAL PROCEDURES 
Subjects 
Adult female Sprague-Dawley rats, weighing 190-270 g, 
were used because they are known to be more susceptible 
than male rats to behavioral sensitization. The animals were 
allowed at least 1 week of acclimatization to the animal 
facilities. During this time, as well as during the subsequent 
experimental period, the rats were housed two or three per 
cage with free access to food and water in a rodent room 
with constant temperature, humidity and a 12 h light-dark 
cycle (0700-1900 light). 
Apparatus 
Locomotor activity of each animal was measured with the 
Digiscan "Micro" system consisting of four mounting frames 
and one analyzer (Omnitech Electronics, Columbus, OH 
43228). A mounting frame contained two parallel panels, 
one photocell panel with 16 infrared light beams spaced 2.54 
cm apart and one light beam detector panel. Each rat was 
placed in a transparent Plexiglas cage (46x24x 18 cm) 
within a mounting frame located in a sound dampened cham- 
ber. The Digiscan system detected locomotor activity by 
counting interruptions of consecutive light beams caused by 
the animal moving from one location to another. Data were 
automatically recorded and processed by the analyzer and 
further transferred to and stored on a Macintosh list 
computer. 
Druqs 
Phencyclidine (National Institute on Drug Abuse, Rock- 
ville, MD 20857) was dissolved in dilute HCI and saline 
(0.9% NaCI) solution. The drug was then neutralized with 
NaOH to give a final pH of approx. 6.4. Phencyclidine was 
administered i.p. once daily for four consecutive days in a 
dose of 3.2 mg/kg. (+)-MK-801 hydrogen maleate 
(Research Biochemicals, Inc., Natick, MA 01760) was dis- 
solved in saline. A dose of 0.32 mg/kg of MK-801 was admin- 
istered i.p. once daily for four consecutive days. 
Proccdblrc 
Rats were randomly divided into three groups Group~ 
were injected with either saline, PCP or MK-801 and tested 
in the Digiscan system daily for four consecutive days. Loco- 
motor activity was assessed immediately following injection 
of each agent. Each animal's activity was monitored con- 
tinuously for the next 120 rain. Data were accunmlated in ll) 
rain blocks throughout the 120 rain period. 
On the fifth day, half of the daily saline-treated rats 
received PCP and the other half received MK-801. Daily 
PCP-treated rats received MK-801 and daily MK-801- 
treated rats received PCP. Rats were tested in the Digiscan 
system immediately after i.p. injection of 3.2 mg/kg PCP or 
0.32 mg/kg MK-801. Motor activity was monitored the same 
as before. 
RESULTS 
Acute administrat ion of  either 3.2 mg/kg PCP or 
0.32 mg/kg MK-801 produced marked increases in 
locomotor  activity over the 2 h sessions compared 
with saline injection (Fig. 1). A one-way A N O V A  
with multiple comparisons on total activity counts 
showed that  the increases in locomotor  activity 
induced by both  agents was significant over the 2 h 
session (F(2,18) = 35.453, P < 0,001). 
While daily saline injection decreased locomotor  
activity, daily administrat ion of  either 3.2 mg/kg PCP 
or 0.32 mg/kg MK-801 resulted in an enhanced loco- 
motor  stimulant effect over four consecutive days 
(Fig. 2). The difference in locomotor  activity between 
the first and fourth injection of  PCP was subjected 
to a correlated t-test, which indicated a statistically 
significant increase (P < 0.01). There were no sig- 
nificant differences between days 2, 3 and 4 for PCP. 
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Fig. 1. Locomotor activity of rats treated with either saline 
or PCP or MK-801 over the 2 h session on day 1. Each bar 
represents the total activity counts in 120 min__+ SE for 5--10 
rats. ***P < 0.001 compared with locomotor activity of rats 
treated with saline. 
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Fig. 2. Locomotor activity of rats treated with either saline 
or PCP or MK-801 over 4 consecutive days. Each bar rep- 
resents the mean total activity counts in 120 min ___ SE for 5- 
10 rats. *P < 0,05, **P < 0.01 compared with related loco- 
motor activity on day 1. 
compared to the fourth injection of MK-801 was also 
statistically significant (P < 0.05). 
The locomotor activity of daily PCP and MK-801 
were analyzed further. The data for each 30 min sub- 
session over the 2 h session on day 1 and day 4 are 
shown in Fig. 3. Daily PCP produced a parallel 
upward shift in locomotor response over the 2 h ses- 
sion without changing its onset and peak action (Fig. 
3 : left panel). Daily MK-801 also induced a upward 
shift in the locomotor response. However, the shift 
was not parallel and the peak of MK-801 was also 
shifted upward after four daily injections (Fig. 3 : right 
panel). 
Despite some similarities between PCP and MK- 
801 in their acute and subchronic effects, asymmetric 
cross-sensitization occurred between the two. The 
PCP-induced locomotor response was significantly 
enhanced after four daily MK-801 injections when 
compared to that after four daily saline injections, 
whereas the MK-801-stimulated locomotor response 
did not show a significant change after four daily PCP 
injections (Fig. 4). 
DISCUSSION 
Acute administration of PCP to rats increases loco- 
motor activity, rearing, stereotypy and ataxia (Green- 
berg and Segal, 1985 ; Iwamoto, 1986; Castellani and 
Adams, 1981). A somewhat similar motor syndrome 
with more ataxia is produced by the acute admin- 
istration of MK-801 (Koek et al., 1988; Hoffman, 
1992). In the present study, both PCP and MK-801 
significantly increased locomotor activity, i.e., from 
one location to another. However, when rats were 
observed through a one-way mirror, only the former 
produced stereotypies and rearing in the doses used. 
Therefore, stereotypy and rearing were not suitable 
behavioral endpoints for this study. In a preliminary 
study, 1.8 mg/kg PCP and 0.18 mg/kg MK-801 were 
used. A dose of 1.8 mg/kg PCP produced much less 
increase in locomotor activity than 3.2 mg/kg PCP, 
while 0.18 mg/kg MK-801 produced a greater increase 
in locomotor activity than 0.32 mg/kg MK-801. How- 
ever, at both doses, PCP produced much more loco- 
motor stimulation than MK-801. Because 0.18 mg/kg 
MK-801 did not produce sensitization to locomotor 
activity in the previous study (Xu and Domino, 1994), 
the present study employed 0.32 mg/kg MK-801. The 
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Fig. 3. Locomotor activity of rats treated with PCP (left panel) and rats treated with MK-801 (fight panel) in 30 min block 
over the 2 h sessions on day 1 and day 4. Each point represents the mean activity counts in 30 rain + SE for 5-6 rats. 
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Future studies should be done using longer periods of 
subchronic treatments. 
Chronic administration of PCP results in an 
enhanced locomotor stimulant effect (Castellani and 
Adams, 1981; Greenberg and Segal, 1985, 1986: lwa- 
moto, 1986: Stergeon et  al. ,  1982). Chronic admin- 
istration of MK-801 also sensitized rats to the 
locomotor stimulant effects of MK-801 (Wolf and 
Khansa, 1991 : Wolf et  al. ,  1993). The results of the 
present study confirmed that chronic administration 
of PCP or MK-801 produce sensitization to their loco- 
motor stimulant effects. However, the neural mech- 
anisms underlying PCP sensitization may differ from 
those of MK-801. Four daily injections of PCP pro- 
duced a parallel upward shift in locomotor response 
pattern over the 2 h session without changing the 
onset and the peak of its action (Fig. 3: left panel), 
while daily MK-801 injections produced a nonparallel 
upward shift in its Locomotor response pattern, with 
the peak action shifted to the left (Fig. 3 : right panel). 
Phencyclidine and MK-801 sensitization may be due 
to changes in the rate of their biotransformation. For 
example PCP is a suicide inhibitor of its own P450 
metabolism (Osawa and Coon, 1989). Nevertheless, 
PCP-induced sensitization has been suggested to be 
due to a pharmacodynamic mechanism (Nabeshima 
et  al., 1987). Whether sensitization induced by both 
agents is due to pharmacokinetic 15ctors needs to be 
investigated further. 
Acute injection of MK-801 in a dose of 0.32 mg/kg 
was observed through a one-way mirror to produce 
severe ataxia, while acute 3.2 mg/kg PCP produced 
mild ataxia (data not shown). No changes in ataxia 
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Fig. 4. Phencyclidine- and MK-801-induced locomotor 
activity after chronic pretreatment with saline, PCP or MK- 
801 respectively. Each bar represents the mean total activity 
counts in 120 min±SE for 5-6 rats. **P < 0.01 compared 
with locomotor activity of chronic-saline rats. 
PCP, which is in agreement with several other studies 
(Greenberg and Segal, 1986; Leccese ef a / ,  1986: 
Smith et  al. ,  1981). Therefore, sensitization induced by 
PCP or MK-801 may not be due to a pharmacokinetic 
factor because a change in all behaviors induced by the 
drugs would be expected if pharmacokinetic lactors 
played a role in sensitization. 
While sensitization to the effects of daily rejection 
of PCP or MK-801 has previously been reported, this 
study is the first to examine their possible cross- 
sensitization. Both PCP and MK-801 enhanced loco- 
motor activity and produced sensitization to 
locomotor activity after daily injection, However, an 
asymmetric cross-sensitization between PCP and MK- 
801 was observed. Phencyclidine-induced locomotor 
activity was enhanced after daily MK-801 injection, 
whereas MK-801-induced locomotor activity did not 
change after daily PCP injection. These results suggest 
that there are important differences in the neuronal 
mechanisms underlying repeated administration o[" 
both drugs. Because PCP sensitized rats did not show 
cross-sensitization to MK-801, it is unlikely that 
NMDA receptors play a major role in the devel- 
opment of PCP sensitization. Reciprocal cross- 
sensitization of locomotion is present between PCP 
and N-allylnormetazocine (NANM), a a ligand 
(Greenberg and Segal, 1986: lwamoto, 1986). Thus 
PCP-induced sensitization may be mediated mainly 
by an interaction with a but not NMDA receptors. In 
another study, daily injections of 0.18 mg/kg of MK- 
801 were administered 30 min before 3.2 mg/kg PCP. 
The rats did not show sensitization to MK-801, but 
showed sensitization to PCP (Xu and Domino, 1994). 
In that study, MK-801 occupied NMDA receptor 
channels without producing sensitization, yet PCP still 
produced sensitization. This further suggests that the 
development of PCP sensitization does not require an 
interaction with the NMDA receptor complex. Future 
studies should compare a binding correlates of differ- 
ent a ligands to establish a role of a receptors in this 
phenomenon. 
In conclusion, although both PCP and MK-801 
enhanced locomotor activity, the development of sen- 
sitization to the former showed a different pattern 
than to the latter. Furthermore, an asymmetric cross- 
sensitization occurred between PCP and MK-801. 
Phencyclidine sensitized animals did not show cross- 
sensitization to MK-801, whereas MK-801 sensitized 
animals showed cross-sensitization to PCP. 
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